The standard workhorse for investigating a suspected stricture is endoscopic retrograde cholangiopancreatography, or ERCP, in which an endoscope is guided to the papilla of Vater and contrast is injected to outline the ducts on X-ray imaging. During the same procedure, clinicians can sample the narrowed segment in two ways. Brush cytology drags a bristled catheter across the lesion and collects shed cells for smear examination, a simple and quick technique with a low complication risk but a disappointingly modest sensitivity, historically around forty-five percent. Transpapillary forceps biopsy, by contrast, physically pinches off tissue from the stricture, yielding true histological architecture rather than isolated cells. In principle this should be more informative, but in practice it is technically demanding, requires considerable operator experience, and has long suffered from a lack of purpose-built instruments, which has kept its success rate relatively low.

The Beijing group, led by Jingxian Wei and Jiangtao Chu with senior author Shun He, set out to close that instrument gap. Their new device is a guidewire-introduced bile duct biopsy forceps with two deliberate design modifications. First, a plastic sheath tube runs alongside the forceps so that the guidewire, already positioned across the stricture, can steer the instrument through the papilla; the sheath keeps the forceps and wire sliding smoothly against each other, solving the chronic problem of guidewire displacement when forceps are repeatedly advanced and withdrawn. Second, the head of the forceps is pre-bent, which helps the jaws angle into the duct rather than scraping perpendicular to its wall. The lengthened guiding sheath and altered jaw angle together raise the technical success rate of biopsy above ninety-five percent in the developers’ design goals, and the device also permits simultaneous collection of bile for cytological examination.

To evaluate the device, the researchers conducted a single-center retrospective study of 262 patients who underwent ERCP for biliary stricture between September 2015 and August 2017. The cohort comprised 157 men and 105 women with an average age of sixty-one years. The final diagnoses were sobering in their distribution: 118 cholangiocarcinomas, 61 pancreatic cancers, 27 ampullary cancers, 16 gallbladder cancers, 23 other cancers, and 17 benign strictures, adding up to 243 malignant and 19 benign narrowings. During each procedure, after fluoroscopic evaluation of the stricture, the guidewire was kept in place across the lesion and the new forceps were advanced over it to attempt a biopsy. When feasible, a cytology brush was then passed as well. All specimens went for pathological and cytological analysis, and the final diagnosis was anchored to histocytological findings plus at least twelve months of clinical follow-up.

The headline numbers tell a clear story about combination testing. Biopsy with the new forceps succeeded in 187 of 262 cases, a technical success rate of 71.4 percent, and achieved a sensitivity for malignancy of 60.8 percent with a diagnostic accuracy of 63.1 percent. Brush cytology was performed in 247 cases, or 94.3 percent of the cohort, and reached a sensitivity of 66.1 percent and an accuracy of 67.6 percent; the brush-based pathology component using cell block technology showed 49.7 percent sensitivity, while exfoliative cytology smears from the same specimens reached 55.7 percent. Crucially, the 176 patients who received both biopsy and brush cytology, 67.2 percent of the cohort, achieved a combined sensitivity of 77.7 percent and an accuracy of 79 percent. Formal pairwise statistical comparison confirmed that the combined approach was significantly better than either method alone, with p-values of 0.012 against brushing and 0.001 against biopsy, while brushing and biopsy alone did not differ significantly from each other. Specificity was a perfect 100 percent for every method, with zero false positives.

Just as striking was the safety profile. The researchers recorded no bleeding, no perforation, no cholangitis, and no post-procedure pancreatitis, and no serious adverse events of any kind. The authors attribute this to the instrument’s design philosophy. Because the forceps slide over a guidewire that has already crossed the papilla, no sphincterotomy is needed, avoiding the cutting of the sphincter muscle that conventional forceps intubation often requires and that raises bleeding risk. Once inside the duct, the wire keeps the forceps aligned within the lumen and steers them toward the narrowed segment, preventing the perpendicular approach to the duct wall that can cause perforation. For patients with obstructive jaundice, endoscopic biliary drainage was performed afterward as routine care, and vital signs were monitored throughout under anesthesia.

The design also dovetails with a broader trend in biliary diagnostics: optimizing specimen collection rather than adding new technology. The authors point to a 2025 multicenter trial by So and colleagues showing that simply flushing residual cells from the brush sheath raised brush cytology sensitivity from 59.2 to 69.9 percent without any change in instruments or procedural steps. The new forceps’ integrated bile collection channel follows the same logic, capturing additional shed cells non-invasively within the conventional workflow, and its 66.1 percent brush sensitivity sits comfortably within the range produced by such specimen-optimization pathways. The message is that incremental refinements in how cells and tissue are harvested can rival the gains expected from expensive new imaging platforms.

The device is not a panacea, and the authors are candid about its limits. The 71.4 percent technical success rate means that in 28.6 percent of cases the forceps could not complete a biopsy, owing to instrument design constraints that sometimes require endoscopic adjustments such as repositioning the forceps flap, or to patient anatomy such as brittle tissue or a narrow opening angle of the jaws. Failure did not correlate closely with the location or severity of the stricture. Beyond the instrument, transpapillary biopsy remains blind under fluoroscopy, cannot reach purely exogenous lesions that compress the duct from outside, and struggles with the fibrous architecture of cholangiocarcinoma and the low cellularity and hardness of pancreatic cancer. Cholangioscopy-guided biopsy offers visual targeting but is costly, uncommon as a routine single-operator technique, and restricted to smaller forceps with lower tissue yield through its working channel.

The study’s own design carries caveats that the authors acknowledge. It was retrospective, single-center, and modest in size, which limits generalizability; the three sampling methods were compared across independent population samples rather than in a paired design in which every patient undergoes all three tests, which would better control for individual heterogeneity; there was no direct head-to-head comparison with conventional biopsy forceps, sheath-based systems, or cholangioscopy; and operator dependence cannot be excluded. The team is now planning a prospective randomized controlled trial to address these gaps and convert the retrospective validation into firmer evidence.

Even with those qualifications, the clinical implications are immediate. Current guidelines for pancreaticobiliary tumors insist on histological or cytological confirmation before treatment, and in centers without access to endoscopic ultrasound, ERCP-based sampling is often the only route to that confirmation. A device that lowers the technical barrier to forceps biopsy, keeps the guidewire stable, avoids sphincterotomy, and pushes combined sensitivity to nearly eighty percent offers a practical upgrade for the many hospitals where cholangioscopy is unavailable. For the roughly seventy percent of patients whose strictures prove malignant, earlier and more reliable tissue diagnosis can mean the difference between resectable and incurable disease; for the quarter whose lesions are benign, it can spare them a major operation they never needed. A modestly redesigned pair of forceps, in other words, may shift one of gastroenterology’s hardest diagnostic calls measurably in the patient’s favor.

Subject of Research: Development and clinical evaluation of guidewire-introduced bile duct biopsy forceps for diagnosing biliary strictures during ERCP

Article Title: Clinical application of a new type of guidewire-introduced bile duct biopsy forceps

Article References: Wei, J., Chu, J., Liu, P., Wang, J., Ke, Y., Liu, X., Zhang, Y., Dou, L., Liu, Y., Liang, R., & He, S. (2026). Clinical application of a new type of guidewire-introduced bile duct biopsy forceps. Holistic Integrative Oncology, 5(1), Article 44. https://doi.org/10.1007/s44178-026-00260-1

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00260-1

Keywords: ERCP, biliary stricture, bile duct biopsy, brush cytology, cholangiocarcinoma, malignant biliary stricture, transpapillary forceps biopsy, guidewire, endoscopy, diagnostic sensitivity, pancreaticobiliary tumors, medical devices